- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07948278
15-Year Follow-up of Protection and Immunity After Bivalent HPV Vaccination in Women (HPV Vaccine)
A 15-Year Follow-up Study of Long-Term Protection and Immunopersistence of an Escherichia Coli-Produced Bivalent HPV-16/18 Vaccine in Healthy Women Aged 18-45 Years
This study aims to evaluate the long-term protection provided by a bivalent HPV vaccine produced in Escherichia coli against specific clinical endpoints related to HPV types 16 and 18 in women aged 18-45 years, as well as the persistence of antibodies specific to these two HPV types.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This observational study is a long-term follow-up of participants in the phase III clinical trial of a bivalent HPV 16/18 vaccine produced in Escherichia coli (HPV-PRO-003, NCT01735006). Women aged 18-45 years at enrollment in the original trial were randomly assigned to receive either the HPV vaccine or a hepatitis E vaccine. The follow-up study will retain the original vaccine and control groups. No additional study intervention will be administered.
Through 15 years after the first dose, this study aims to evaluate the long-term protection provided by the bivalent HPV vaccine against specific clinical endpoints associated with HPV types 16 and/or 18 and to assess the persistence of antibodies specific to HPV types 16 and 18.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Ting Wu
- Telefoonnummer: 0592-2880621
- E-mail: wuting.@xmu.edu.cn
Studie Locaties
-
-
Guangxi
-
Liuzhou, Guangxi, China, 545007
- Liuzhou Center for Disease Control and Prevention
-
Contact:
- Haibo Wang, MSc
- Telefoonnummer: +86-772-3720738
- E-mail: lzcdcxmb@163.com
-
-
Hebei
-
Fengning, Hebei, China, 068350
- Fengning Hospital of Traditional Chinese Medicine
-
Contact:
- Cuihong Dai, BSc
- Telefoonnummer: +86-314-8080327
- E-mail: wxn_cdfn@126.com
-
-
Henan
-
Qingpingjie, Henan, China, 452370
- Xinmi Maternal and Child Health Hospital
-
Contact:
- Fengxian Zheng, BSc
- Telefoonnummer: +86-371-69833851
- E-mail: 513940819@qq.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
The study population comprises women who received at least one dose of their assigned vaccine in the original phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003). To be eligible, women must not have received any HPV vaccine outside their original trial assignment since enrollment in that trial, including any subsequent catch-up doses given to control group participants. Participants retain their original group assignments (HPV vaccine group or hepatitis E vaccine control group).
Beschrijving
Inclusion Criteria:
- The participant took part in the phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003) and received at least one dose of the vaccine assigned to her in that trial.
- The participant has given informed consent and signed the consent form.
- The participant is able to complete all study procedures as required by the protocol.
Exclusion Criteria:
- Since enrollment in the original phase III trial, the participant has received any HPV vaccine other than the study vaccination assigned under the original trial protocol. This includes subsequent catch-up vaccination with the investigational vaccine among participants in the original control group, as well as receipt of any other licensed or unlicensed HPV vaccine.
- The participant had an invasive malignancy of the cervix, vagina, or vulva before enrollment in this follow-up study, or an abnormality detected at screening is confirmed to be an invasive malignancy at one of these sites by histopathological examination of a colposcopy-directed biopsy specimen.
- In the investigator's judgment, a medical, psychological, social, occupational, or other circumstance would interfere with the participant's ability to comply with the protocol or to provide written informed consent.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Vaccine group
Women assigned to the vaccine group in the original phase III trial who received at least one dose of the bivalent HPV 16/18 vaccine. Since enrollment in the original trial, they must not have received any HPV vaccine other than the study vaccine administered as specified in that trial's protocol. Participants must also meet all other eligibility criteria for this follow-up study. |
The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant |
|
Control group
Women assigned to the control group in the original phase III trial who received at least one dose of control vaccine (hepatitis E vaccine). Since enrollment in the original trial, they must not have received any HPV vaccine other than vaccination specified in the original trial protocol. Participants must also meet all other eligibility criteria for this follow-up study. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
CIN2+, VIN2+, or VaIN2+ associated with HPV type 16 or 18 in the per-protocol population
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 2 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
6-month persistent infection with HPV type 16 or 18 in the per-protocol population
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
Infection with the same HPV type must persist for at least 6 months |
At months 156 and 180 after the first dose in the original trial
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
CIN1+, VIN1+, or VaIN1+ associated with HPV type 16 or 18
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 1 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
CIN2+ associated with HPV type 16 or 18
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 2 or worse cervical intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
VIN2+, or VaIN2+ associated with HPV type 16 or 18
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
This endpoint includes grade 2 or worse vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types |
At months 156 and 180 after the first dose in the original trial
|
|
HPV-16-specific infection and/or lesion endpoints
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
6-month persistent infection and grade 2 or worse cervical intraepithelial |
At months 156 and 180 after the first dose in the original trial
|
|
HPV-18-specific infection and/or lesion endpoints
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
6-month persistent infection and grade 2 or worse cervical intraepithelial |
At months 156 and 180 after the first dose in the original trial
|
|
Type-specific infection and/or lesion endpoints associated with other high-risk HPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
6-month persistent infection and grade 2 or worse cervical intraepithelial |
At months 156 and 180 after the first dose in the original trial
|
|
Type-specific seropositivity rates for HPV-16 and HPV-18 antibodies
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
Percentage of participants seropositive for HPV-16 and HPV-18 antibodies |
At months 156 and 180 after the first dose in the original trial
|
|
Type-specific HPV-16 and HPV-18 antibody levels
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
Serum antibody titers against HPV-16 and HPV-18 |
At months 156 and 180 after the first dose in the original trial
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
incident HPV-16 and/or HPV-18 infection
Tijdsspanne: At months 156 and 180 after the first dose in the original trial
|
Newly detected HPV-16 and/or HPV-18 DNA positivity |
At months 156 and 180 after the first dose in the original trial
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Jun Zhang, Xiamen University
- Hoofdonderzoeker: Ting Wu, Xiamen University
Publicaties en nuttige links
Algemene publicaties
- Zhao F, Chen Q, Zhao C, Nie L, Hu S, Yin J, Qiu L, Bi Z, Quan J, Li Y, Li M, Zhang X, Pan Q, Li C, Ke L, Liu X, Zheng F, Dai C, Wang Z, Kuang X, Jia X, Su Y, Huang S, Zhang Q, Huang W, Wei L, Zhang J, Wu T, Qiao Y, Xia N. Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort. Lancet Reg Health West Pac. 2025 Aug 21;61:101668. doi: 10.1016/j.lanwpc.2025.101668. eCollection 2025 Aug.
- Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, Chen W, Huang SJ, Pan QJ, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang YF, Li MZ, Tang J, Li CH, Guo DP, Ke LD, Wu X, Yao XM, Nie JH, Lin BZ, Zhao YQ, Guo M, Zhao J, Zheng FZ, Xu XQ, Su YY, Zhang QF, Sun G, Zhu FC, Li SW, Li YM, Pan HR, Zhang J, Qiao YL, Xia NS. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis. 2022 Dec;22(12):1756-1768. doi: 10.1016/S1473-3099(22)00435-2. Epub 2022 Aug 26.
- Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, Chen W, Huang SJ, Zhao FH, Li MQ, Pan QJ, Zhang X, Li Q, Hong Y, Zhao C, Zhang WH, Li YP, Chu K, Li M, Jiang YF, Li J, Zhao H, Lin ZJ, Cui XL, Liu WY, Li CH, Guo DP, Ke LD, Wu X, Tang J, Gao GQ, Li BY, Zhao B, Zheng FX, Dai CH, Guo M, Zhao J, Su YY, Wang JZ, Zhu FC, Li SW, Pan HR, Li YM, Zhang J, Xia NS. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. J Natl Cancer Inst. 2020 Feb 1;112(2):145-153. doi: 10.1093/jnci/djz074.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Pathologische processen
- Neoplasmata
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Ziekte attributen
- Infecties
- Baarmoeder Ziekten
- Genitale ziekten, vrouw
- Voorstadia van kanker
- Baarmoederhalsaandoeningen
- Pathologische aandoeningen, tekenen en symptomen
- Aanhoudende infectie
- Baarmoederhalsdysplasie
- Biologische producten
- Complexe mengsels
- Vaccins
Andere studie-ID-nummers
- HPV-PRO-003-4
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Proposals should be sent to the Principal Investigator. Proposals will be reviewed and approved by the study team.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .